Study S000776

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03130426
Acronym: REMIT-iGL
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 161
Start: 2017-06-27
Primary completion: 2019-06-30
Lead sponsor: Population Health Research Institute
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:iGlarLixi; DRUG:Insulin Glargine; DRUG:Metformin; BEHAVIORAL:Lifestyle therapy
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The first occurrence of diabetes relapse [64 weeks of follow-up]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.